Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non –ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial
Conclusions Doubling the ticagrelor LD achieved faster onset and greater platelet inhibition without an increase in adverse events in patients with NSTE-ACS undergoing PCI.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
More News: Angioplasty | Bleeding | Canada Health | Cardiology | Coronary Angioplasty | Heart | Heart Attack | Percutaneous Coronary Intervention | Stroke